SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al, and the European Vasculitis Study Group (EUVAS). Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67: 100410.
  • 2
    Jayne D. Review article: progress of treatment in ANCA-associated vasculitis [review]. Nephrology 2009; 14: 428.
  • 3
    Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE) [abstract]. Arthritis Rheum 2009; 60 Suppl: S204.
  • 4
    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al, and the RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 22132.
  • 5
    Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al, and the European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 21120.
  • 6
    Whitney SN, McGuire AL, McCullough LB. A typology of shared decision making, informed consent, and simple consent. Ann Intern Med 2004; 140: 5460.
  • 7
    Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 7415.
  • 8
    Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year followup study. Arthritis Rheum 1995; 38: 11207.
  • 9
    Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann Intern Med 1996; 124: 47784.
  • 10
    Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35: 1005.
  • 11
    Trevena LJ, Davey HM, Barratt A, Butow P, Caldwell P. A systematic review on communicating with patients about evidence. J Eval Clin Pract 2006; 12: 1323.
  • 12
    Peters E. The functions of affect in the construction of preferences. In: LichtensteinS, SlovicP, editors. The construction of preference. New York: Cambridge University Press; 2006. p. 45463.
  • 13
    Slovic P, Finucane ML, Peters E, MacGregor DG. The affect heuristic. Eur J Oper Res 2007; 177: 133352.
  • 14
    Slovic P, Peters E. Risk perception and affect. Curr Direct Psychol Sci 2006; 15: 3225.
    Direct Link:
  • 15
    Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008; 30: 908.